News
CMS decision on Aduhelm is in, and it's bad news for Biogen
The US Centres for Medicare and Medicaid Services (CMS) has firmed up its draft decision to limit reimbursement of Biogen's Alzheimer's disease therapy Aduhelm to a few thousand patients en
